Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-28T13:11:49.609Z Has data issue: false hasContentIssue false

2.24 - Trihexyphenidyl

from Medications for Motor/Neurologic Adverse Effects

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Typical or first-generation antipsychotic (FGA)

Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 213
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Szafranski, T., Gmurkowski, K. (1999). Clozapine withdrawal. A review. Psychiatr Pol, 33, 51–67.Google ScholarPubMed
Faulkner, M. A. (2014). Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opin Drug Saf, 13, 1055–1069.CrossRefGoogle ScholarPubMed
Thenganatt, M. A., Jankovic, J. (2014). Treatment of dystonia. Neurotherapeutics, 11, 139–152.CrossRefGoogle ScholarPubMed
Orayj, K., Lane, E. (2019). Patterns and determinants of prescribing for Parkinson’s disease: a systematic literature review. Parkinsons Dis, 2019, 9237181.Google ScholarPubMed
PubChem. (2020). Trihexyphenidyl, CID = 5572. Retrieved April 21, 2020.Google Scholar
Modell, J. G., Tandon, R., Beresford, T. P. (1989). Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol, 9, 347–351.CrossRefGoogle ScholarPubMed
Deleu, D., Northway, M. G., Hanssens, Y. (2002). Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet, 41, 261–309.CrossRefGoogle ScholarPubMed
Robottom, B. J., Weiner, W. J., Factor, S. A. (2011). Movement disorders emergencies. Part 1: hypokinetic disorders. Arch Neurol, 68, 567–572.Google ScholarPubMed
Rajan, S., Kaas, B., Moukheiber, E. (2019). Movement disorders emergencies. Semin Neurol, 39, 125–136.CrossRefGoogle ScholarPubMed
Mazzucchi, S., Frosini, D., Bonuccelli, U., et al. (2015). Current treatment and future prospects of dopa-induced dyskinesias. Drugs Today (Barc), 51, 315–329.CrossRefGoogle ScholarPubMed
Barbe, A. G. (2018). Medication-induced xerostomia and hyposalivation in the elderly: culprits, complications, and management. Drugs Aging, 35, 877–885.CrossRefGoogle ScholarPubMed
Andre, L., Gallini, A., Montastruc, F., et al. (2019). Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. Eur J Clin Pharmacol, 75, 1631–1644.CrossRefGoogle ScholarPubMed
Ogino, S., Miyamoto, S., Miyake, N., et al. (2014). Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci, 68, 37–49.CrossRefGoogle ScholarPubMed
Kopala, L. C. (1996). Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand Suppl, 389, 12–17.CrossRefGoogle ScholarPubMed
Gao, K., Kemp, D. E., Ganocy, S. J., et al. (2008). Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol, 28, 203–209.CrossRefGoogle ScholarPubMed
Lupu, A. M., Clinebell, K., Gannon, J. M., et al. (2017). Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. J Clin Psychiatry, 78, e1270–e1275.CrossRefGoogle ScholarPubMed
Close, S. P., Elliott, P. J., Hayes, A. G., et al. (1990). Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson’s disease. Psychopharmacology (Berl), 102, 295–300.CrossRefGoogle Scholar
Meyer, S., Meyer, O., Kressig, R. W. (2010). Drug-induced delirium. Ther Umsch, 67, 79–83.CrossRefGoogle ScholarPubMed
Onder, G., Liperoti, R., Foebel, A., et al. (2013). Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study. J Am Med Dir Assoc, 14(6), 450 e7–12.Google Scholar
Robles Bayon, A., Gude Sampedro, F. (2014). Inappropriate treatments for patients with cognitive decline. Neurologia, 29, 523–532.Google ScholarPubMed
Ueki, T., Nakashima, M. (2019). Relationship between constipation and medication. J UOEH, 41, 145–151.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Trihexyphenidyl
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Trihexyphenidyl
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Trihexyphenidyl
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×